ETV3L

Across TCGA pan-cancer cohorts, ETV3L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ETV3L data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ETV3L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ETV3L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LIHC, LUSC, and COAD are the cancer types where ETV3L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.051	0.696	<.001	24	view →
LUSC	OS	Median	All	0.170	0.662	<.001	19	view →
COAD	OS	Median	All	0.158	0.674	.006	13	view →
HNSC	DFS	Median	All	0.133	0.625	.040	3	view →
SKCM	OS	Median	All	0.115	0.343	.015	3	view →
UCEC	DFS	Median	All	1.000	0.631	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ETV3L–LIHC (OS)

Open the LIHC breakdown →